Tevogen Bio Holdings Inc (TVGN)

$1.18 +0.02 (1.72%)
Market Cap 213.32M
Revenue (ttm) 0.00
Net Income (ttm) -13.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.39
Volume 346,900
Avg Vol 1,077,074
Day's Range N/A - N/A
Shares Out 183.89M
Stochastic %K 18%
Beta -0.70
Analysts Strong Sell
Price Target $10.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6434
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #410, Warren, United States
BigBagSniper
BigBagSniper Jun. 24 at 3:59 PM
$TVGN the way this is holding, someone may know something 🤞🏾
1 · Reply
BigBagSniper
BigBagSniper Jun. 24 at 1:10 PM
$TVGN nothing in the 8k for us, expecting a drop from here without any significant juice to bring volume
1 · Reply
Xooze
Xooze Jun. 24 at 12:41 PM
$TVGN there is an 8k out, but not much news?
0 · Reply
Quadeagle
Quadeagle Jun. 24 at 10:27 AM
$TVGN
1 · Reply
Landomos
Landomos Jun. 23 at 7:01 PM
$TVGN
0 · Reply
Rapps22
Rapps22 Jun. 23 at 6:34 PM
$TVGN Anyone have any updates from the annual meeting!?
3 · Reply
robsmi63
robsmi63 Jun. 23 at 2:14 PM
$TVGN the future "billion dollar" company needs money? Go figure
0 · Reply
Quadeagle
Quadeagle Jun. 23 at 2:08 PM
$TVGN
0 · Reply
BigBagSniper
BigBagSniper Jun. 23 at 1:54 PM
$TVGN feels like we are floating in the Dead Sea.. This needs juice
0 · Reply
NGCS
NGCS Jun. 23 at 9:46 AM
$TVGN what time is the meeting?
2 · Reply
Latest News on TVGN
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Jun 18, 2025, 8:30 AM EDT - 6 days ago

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Jun 9, 2025, 9:00 AM EDT - 15 days ago

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025, 11:01 AM EDT - 25 days ago

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

May 23, 2025, 3:49 PM EDT - 4 weeks ago

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

May 22, 2025, 1:21 PM EDT - 4 weeks ago

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

May 12, 2025, 8:00 AM EDT - 6 weeks ago

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 2, 2025, 3:45 PM EDT - 7 weeks ago

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Apr 30, 2025, 3:49 PM EDT - 7 weeks ago

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Apr 29, 2025, 1:48 PM EDT - 2 months ago

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Apr 29, 2025, 8:00 AM EDT - 2 months ago

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Apr 28, 2025, 4:36 PM EDT - 2 months ago

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen Bio Announces 2025 Annual Meeting

Apr 25, 2025, 2:33 PM EDT - 2 months ago

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Apr 17, 2025, 2:54 PM EDT - 2 months ago

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Apr 15, 2025, 2:03 PM EDT - 2 months ago

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

Apr 9, 2025, 2:45 PM EDT - 2 months ago

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Apr 8, 2025, 5:53 PM EDT - 2 months ago

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission

Apr 7, 2025, 3:58 PM EDT - 2 months ago

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Mar 26, 2025, 3:12 PM EDT - 3 months ago

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Mar 25, 2025, 1:11 PM EDT - 3 months ago

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Mar 10, 2025, 12:40 PM EDT - 3 months ago

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Mar 7, 2025, 4:09 PM EST - 3 months ago

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Mar 4, 2025, 1:52 PM EST - 4 months ago

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Mar 3, 2025, 12:52 PM EST - 4 months ago

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Feb 28, 2025, 1:17 PM EST - 4 months ago

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Feb 21, 2025, 3:28 PM EST - 4 months ago

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Feb 14, 2025, 6:31 PM EST - 4 months ago

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Feb 14, 2025, 1:16 PM EST - 4 months ago

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Feb 14, 2025, 11:52 AM EST - 4 months ago

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Feb 13, 2025, 4:34 PM EST - 4 months ago

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

Feb 7, 2025, 2:56 PM EST - 4 months ago

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Jan 28, 2025, 3:49 PM EST - 5 months ago

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Jan 27, 2025, 2:24 PM EST - 5 months ago

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Jan 24, 2025, 5:34 PM EST - 5 months ago

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Jan 23, 2025, 7:53 PM EST - 5 months ago

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Dec 26, 2024, 12:21 PM EST - 6 months ago

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 9:38 AM EST - 6 months ago

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Dec 19, 2024, 8:30 AM EST - 6 months ago

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound

Dec 18, 2024, 2:29 AM EST - 6 months ago

Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 1:32 PM EST - 6 months ago

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 3:13 PM EST - 7 months ago

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Dec 5, 2024, 11:03 AM EST - 7 months ago

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

Nov 26, 2024, 8:05 AM EST - 7 months ago

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Nov 21, 2024, 3:59 PM EST - 7 months ago

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Nov 19, 2024, 4:50 PM EST - 7 months ago

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Nov 14, 2024, 5:00 PM EST - 7 months ago

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Nov 14, 2024, 3:49 PM EST - 7 months ago

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Nov 8, 2024, 3:36 PM EST - 8 months ago

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Nov 5, 2024, 9:27 AM EST - 8 months ago

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Nov 4, 2024, 2:36 PM EST - 8 months ago

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Oct 31, 2024, 10:54 AM EDT - 8 months ago

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

BigBagSniper
BigBagSniper Jun. 24 at 3:59 PM
$TVGN the way this is holding, someone may know something 🤞🏾
1 · Reply
BigBagSniper
BigBagSniper Jun. 24 at 1:10 PM
$TVGN nothing in the 8k for us, expecting a drop from here without any significant juice to bring volume
1 · Reply
Xooze
Xooze Jun. 24 at 12:41 PM
$TVGN there is an 8k out, but not much news?
0 · Reply
Quadeagle
Quadeagle Jun. 24 at 10:27 AM
$TVGN
1 · Reply
Landomos
Landomos Jun. 23 at 7:01 PM
$TVGN
0 · Reply
Rapps22
Rapps22 Jun. 23 at 6:34 PM
$TVGN Anyone have any updates from the annual meeting!?
3 · Reply
robsmi63
robsmi63 Jun. 23 at 2:14 PM
$TVGN the future "billion dollar" company needs money? Go figure
0 · Reply
Quadeagle
Quadeagle Jun. 23 at 2:08 PM
$TVGN
0 · Reply
BigBagSniper
BigBagSniper Jun. 23 at 1:54 PM
$TVGN feels like we are floating in the Dead Sea.. This needs juice
0 · Reply
NGCS
NGCS Jun. 23 at 9:46 AM
$TVGN what time is the meeting?
2 · Reply
BigBagSniper
BigBagSniper Jun. 21 at 2:13 PM
$TVGN if they were smart, they would pump the price before diluting Usually the case. Expecting some significant pumping PR for the annual meeting, then dilution. Play accordingly.. if you are long just strap in lol
1 · Reply
DonCorleone77
DonCorleone77 Jun. 21 at 1:42 PM
$TVGN Tevogen files $150M mixed securities shelf
1 · Reply
FilingTracker
FilingTracker Jun. 20 at 9:26 PM
$TVGN $150,000,000 Prospectus:
1 · Reply
Rapps22
Rapps22 Jun. 20 at 1:39 PM
$TVGN Yup LFG! ….Monday annual meeting, potential PR(s) id say incoming!
0 · Reply
Quadeagle
Quadeagle Jun. 20 at 10:10 AM
$TVGN
0 · Reply
dcme010711
dcme010711 Jun. 18 at 3:46 PM
$TVGN
0 · Reply
dcme010711
dcme010711 Jun. 18 at 3:45 PM
$TVGN buy and PT reiterated
0 · Reply
Quadeagle
Quadeagle Jun. 18 at 1:36 PM
$TVGN Adding
0 · Reply
Quadeagle
Quadeagle Jun. 18 at 12:31 PM
$TVGN we got some news
2 · Reply
Andymac1966
Andymac1966 Jun. 18 at 11:05 AM
$TVGN I really thought that release some juicy news before annual meeting but so far nothing
1 · Reply
Quadeagle
Quadeagle Jun. 18 at 10:28 AM
$TVGN
0 · Reply
Thenailguy
Thenailguy Jun. 18 at 1:39 AM
$TVGN I loaded up 240k shares.
0 · Reply